Wockhardt's ZAYNICH (Zidebactam) gets CDSCO marketing nod

Indian drug regulator CDSCO granted marketing authorization to Wockhardt's novel antibiotic ZAYNICH (Zidebactam), a beta-lactamase inhibitor combination effective against multidrug-resistant Gram-negative infections. While not a first-line dental drug, it is relevant for managing severe odontogenic infections or post-surgical sepsis where resistance is a concern. Availability in India is expected soon; no specific dental dosage noted yet.